多靶点激酶抑制剂治疗肝细胞癌研究进展  

Advance on multitargeted kinase inhibitor in treatment of hepatocellular carcinoma

作　　者：何春晓[1] 宋正波[1] 张沂平[1] 

机构地区：[1]浙江省肿瘤医院化疗中心,浙江杭州310022

出　　处：《中国新药与临床杂志》2014年第3期167-173,共7页Chinese Journal of New Drugs and Clinical Remedies

基　　金：浙江省中医药科学研究基金计划(2012ZA022);浙江省医药卫生科学研究基金(2007B025);吴阶平医学基金(320.6750.11059;320.6750.11091;320.6799.1106)

摘　　要：随着细胞分子生物学等基础研究的发展,肝细胞癌的靶向治疗取得了较大的发展。索拉非尼是第一个被推荐作为晚期肝细胞癌治疗的一线药物,但其对晚期肝细胞癌患者总生存期的影响仍有限。目前多个针对肝细胞癌的分子靶点的多靶点激酶抑制剂正在研究中。本文旨在回顾并总结肝细胞癌的治疗靶点及多靶点激酶抑制剂的治疗进展。With the development of basic research in cellular and molecular biology, targeted therapy of hepatocellular carcinoma has a larger development. Sorafenib is recommended as first- line drug to treatmentadvanced hepatocellular carcinoma, however its impact on the overall survival of patients with advanced hepatocellular carcinoma is still limited. Multitargeted kinase inhibitors focused on molecular targets for hepatocellular carcinoma is being studied. This article aims to review and summarize the therapeutic targets of hepatocellular carcinoma and the advance on therapy of hepatocellular carcinoma with multitargeted kinase inhibitors.

关 键 词：癌 肝细胞 分子靶向治疗 多靶点 受体 表皮生长因子 索拉非尼 

分 类 号：R979.1[医药卫生—药品]